Evaluation of the Long-term Administration of Rifaximin for More than Three Years in the Treatment of Repeated and Recurrent Overt Hepatic Encephalopathy

被引:2
|
作者
Fujiwara, Yudai [1 ,2 ]
Suzuki, Kazuyuki [1 ,2 ]
Yusa, Kenji [1 ,2 ]
Eizuka, Makoto [2 ]
Miura, Manami [2 ]
Watanabe, Yuki [1 ,2 ]
Takahashi, Hiroshi [2 ]
Takikawa, Yasuhiro [1 ]
机构
[1] Iwate Med Univ, Dept Internal Med, Div Hepatol, Yahaba, Iwate, Japan
[2] Iwate Prefectural Ninohe Hosp, Dept Gastroenterol, Ninohe, Iwate, Japan
关键词
rifaximin; liver cirrhosis; overt hepatic encephalopathy; hyperammonemia; PORTAL-SYSTEMIC ENCEPHALOPATHY; LIVER-CIRRHOSIS; PRIMARY PROPHYLAXIS; CARNITINE; ZINC; DIAGNOSIS;
D O I
10.2169/internalmedicine.5793-20
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The patient was a 65-year-old man with alcoholic liver cirrhosis who had been admitted to hospital 5 times for repeated and recurrent overt hepatic encephalopathy (HE) despite numerous therapies, including disaccharide, branched-chain amino acid (BCAA) formula. L-carnitine and zinc. After the additional administration of rifaximin (1,200 mg/day orally), his consciousness level was well controlled for 3 years without any adverse effects. The long-term administration of rifaximin may be useful and safe for managing recurrent overt HE, although the maintenance dosage and duration of rifaximin and safety should be evaluated in patients with ameliorated HE.
引用
收藏
页码:1027 / 1033
页数:7
相关论文
共 50 条
  • [1] Efficacy of long-term rifaximin treatment for hepatic encephalopathy in the Japanese
    Nishida, Shinya
    Hamada, Koichi
    Nishino, Noriyuki
    Fukushima, Daizo
    Koyanagi, Ryota
    Horikawa, Yoshinori
    Shiwa, Yoshiki
    Saitoh, Satoshi
    WORLD JOURNAL OF HEPATOLOGY, 2019, 11 (06) : 531 - 541
  • [2] Efficacy of long-term rifaximin treatment for hepatic encephalopathy in the Japanese
    Shinya Nishida
    Koichi Hamada
    Noriyuki Nishino
    Daizo Fukushima
    Ryota Koyanagi
    Yoshinori Horikawa
    Yoshiki Shiwa
    Satoshi Saitoh
    World Journal of Hepatology, 2019, (06) : 531 - 541
  • [3] Rifaximin Is Safe and Well Tolerated for Long-term Maintenance of Remission From Overt Hepatic Encephalopathy
    Mullen, Kevin D.
    Sanyal, Arun J.
    Bass, Nathan M.
    Poordad, Fred F.
    Sheikh, Muhammad Y.
    Frederick, R. Todd
    Bortey, Enoch
    Forbes, William P.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2014, 12 (08) : 1390 - +
  • [4] Rifaximin has a Favorable Long-Term Safety Profile for Maintenance of Remission from Overt Hepatic Encephalopathy
    Sheikh, Muhammad
    Bass, Nathan
    Sanyal, Arun
    Poordad, Fred
    Mullen, Kevin
    Sigal, Samuel
    Frederick, Todd
    Bhandari, Bal Raj
    Vemuru, Ravikumar
    Huang, Shirley
    Merchant, Kunal
    Shaw, Audrey
    Bortey, Enoch
    Forbes, William
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2009, 104 : S136 - S136
  • [5] Long-Term Survival Following Overt Hepatic Encephalopathy
    Neff, Guy
    Christian, Macnish
    Ramirez, Maxx
    Webster, Hannah
    Galambo, Faris
    Palamittam, Dylan
    Parkinson, Erin
    Cece, Elizabeth
    Cooper, Jennifer
    Alsina, Angel
    Mendoza, Alfredo
    Kemmer, Nyingi
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2012, 107 : S606 - S606
  • [6] Long-term management of hepatic encephalopathy with lactulose and/or rifaximin: a review of the evidence
    Hudson, Mark
    Schuchmann, Marcus
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2019, 31 (04) : 434 - 450
  • [7] Real-world effects of long-term rifaximin treatment for Japanese patients with hepatic encephalopathy
    Suzuki, Hiroyuki
    Sezaki, Hitomi
    Suzuki, Fumitaka
    Kasuya, Kayoko
    Sano, Tomoya
    Fujiyama, Shunichiro
    Kawamura, Yusuke
    Hosaka, Tetsuya
    Akuta, Norio
    Saitoh, Satoshi
    Kobayashi, Masahiro
    Arase, Yasuji
    Ikeda, Kenji
    Suzuki, Yoshiyuki
    Kumada, Hiromitsu
    HEPATOLOGY RESEARCH, 2019, 49 (12) : 1406 - 1413
  • [8] The Long Term Efficacy and Safety of Rifaximin in the Maintenance of Remission From Overt Hepatic Encephalopathy in Cirrhotic Patients
    Mullen, Kevin D.
    Sanyal, Arun J.
    Bass, Nathan M.
    Poordad, Fred
    Huang, Shirley
    Merchant, Kunal
    Bortey, Enoch
    Forbes, William P.
    GASTROENTEROLOGY, 2012, 142 (05) : S41 - S42
  • [9] LONG TERM CARE SERVICES USE AMONG MEDICARE PATIENTS TREATED WITH RIFAXIMIN FOR OVERT HEPATIC ENCEPHALOPATHY
    Gagnon-Sanschagrin, Patrick
    Heimanson, Zeev
    Allen, Christopher
    Maitland, Jessica
    Davidson, Mikhail
    Zhang, Adina
    Chen, Jingyi
    Guerin, Annie
    Dashputre, Ankur A.
    Bumpass, Brock
    Olujohungbe, Olamide
    Borroto, Danellys
    Joseph, George
    GASTROENTEROLOGY, 2023, 164 (06) : S1400 - S1400
  • [10] Rifaximin plus lactulose is more effective than lactulose alone for the prevention of overt hepatic encephalopathy in patients with or without diabetes
    Bajaj, Jasmohan S.
    Wong, Robert
    Heimanson, Zeev
    Allen, Christopher
    Israel, Robert
    Sanyal, Arun
    JOURNAL OF HEPATOLOGY, 2023, 78 : S236 - S236